Nexalin Technology, Inc. (NASDAQ:NXL) Sees Significant Decline in Short Interest

Nexalin Technology, Inc. (NASDAQ:NXL) was the recipient of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totalling 74,800 shares, a decrease of 93.6% from the June 30th total of 1,170,000 shares. Currently, 1.2% of the company’s stock are short sold. Based on an average daily volume of 2,680,000 shares, the days-to-cover ratio is presently 0.0 days.

Nexalin Technology Stock Down 0.8 %

Shares of NXL stock traded down $0.01 during trading hours on Thursday, reaching $1.17. The company had a trading volume of 136,323 shares, compared to its average volume of 1,587,627. Nexalin Technology has a 12 month low of $0.25 and a 12 month high of $4.05. The business has a fifty day simple moving average of $1.25 and a 200-day simple moving average of $1.02.

Nexalin Technology (NASDAQ:NXL) last issued its quarterly earnings data on Friday, May 10th. The company reported ($0.14) earnings per share for the quarter. Nexalin Technology had a negative net margin of 3,088.12% and a negative return on equity of 154.84%. The company had revenue of $0.08 million for the quarter.

Nexalin Technology Company Profile

Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.